ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 15 for:    FerInject | Germany

Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02469480
Recruitment Status : Recruiting
First Posted : June 11, 2015
Last Update Posted : January 11, 2018
Sponsor:
Information provided by (Responsible Party):
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest

Brief Summary:
Iron deficiency has a high prevalence in colorectal cancer patients ranging at ca. 60%. About 70% of these patients suffer from iron deficiency anemia (IDA) which adds both physical and cognitive impediments to an already straining chemotherapy. Moreover, a chronic disease like cancer often results in a reduced availability of iron for the body. In clinical practice iron substitution is usually administered orally. Due to low resorption rates, frequent gastric side effects and thus poor patient compliance a parenteral substitution seems to be a better option in terms of efficacy. In the framework of a randomized multicenter clinical trial ('FerInject') a comparison of efficacy parameters of parenteral vs. oral iron substitution will now be conducted in order to identify the best treatment form for clinical practice in oncology. Furthermore detailed quality of life-data (QoL) will be collected in both treatment arms for effect comparison.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: FerInject Drug: Ferro sanol Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.
Study Start Date : March 2015
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: FERRIC CARBOXYMALTOSE
max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
Drug: FerInject
FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).

Active Comparator: ferro sanol(R) duodenal 100 mg
200 mg ferro sanol per day over 12 weeks
Drug: Ferro sanol
200 mg ferro sanol per day over 12 weeks




Primary Outcome Measures :
  1. Rise or normalization of hemoglobin [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Fatigue as measured by EORTC-QLQ-FA13 [ Time Frame: 12 weeks ]
  2. Quality of life as measured by EORTC-C30 [ Time Frame: 12 weeks ]
  3. Handgrip strength as measured by Hydraulic Hand Dynamometer [ Time Frame: 12 weeks ]
  4. Number of allogenic blood transfusions (in total and per patient) [ Time Frame: 12 weeks ]
  5. Time until rise or normalisation of hemoglobin [ Time Frame: 12 weeks ]
  6. Genesis of the iron deficiency anemia [ Time Frame: 12 weeks ]
  7. Number of therapy with recombinant erythropoietin [ Time Frame: 12 weeks ]
  8. Dose of therapy with recombinant erythropoietin [ Time Frame: 12 weeks ]
  9. Duration of therapy with recombinant erythropoietin [ Time Frame: 12 weeks ]
  10. Inflammatory parameters [ Time Frame: 12 weeks ]
  11. Influence nutritional status on iron deficiency anemia as measured by Nutritional Risk Screening (NRS 2002) [ Time Frame: 12 weeks ]
  12. Influence nutritional status on therapy success as measured by Nutritional Risk Screening (NRS 2002) [ Time Frame: 12 weeks ]
  13. Tolerance [ Time Frame: 12 weeks ]
  14. Toxicity [ Time Frame: 12 weeks ]
  15. Dropout rate due to toxicity or patient will [ Time Frame: 12 weeks ]
  16. Overall survival [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Metastatic or inoperable colorectal carcinoma. No curative therapy available.
  2. Current palliative chemotherapy. Patients under conversion therapy must not be enrolled to this study.
  3. Iron deficiency anemia: hemoglobin ≤ 10.5 g/dl and transferrin saturation < 20 % and/or serum ferritin < 20 ng/ml
  4. Male and female patients aged ≥ 18 years; maturity
  5. ECOG ≤ 2
  6. Written informed consent
  7. Life expectancy > 6 months
  8. Body weight ≥ 40 kg

Exclusion Criteria:

  1. Oral or intravenous iron substitution within the last 4 weeks
  2. Age < 18 years or body weight < 40 kg
  3. Absorption dysfunction due to short bowel syndrome or after gastric resection
  4. Therapy with recombinant erythropoietin within the last 4 weeks
  5. Chronic diarrhea
  6. Chronic inflammatory bowel disease
  7. Ferritin > 800 mg/dl at baseline
  8. Hypersensitivity or contraindication to ferric carboxymaltose or iron (II) glycine sulphate complex
  9. Known vitamin B12 or folic acid anemia
  10. Necessary total parenteral nutrition
  11. Participation in another interventional study
  12. Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02469480


Contacts
Contact: Salah-Eddin Al-Batran, Professor +496976014420 albatran.salah@khnw.de
Contact: Gerrit zur Hausen, PhD +496976014562 zurhausen.gerrit@khnw.de

Locations
Germany
Krankenhaus Nordwest gGmbH - Institut of Clinical Cancer Research Recruiting
Frankfurt am Main, Hesse, Germany, 60488
Contact: Salah-Eddin Al-Batran, Professor    +496976014420    albatran.salah@khnw.de   
Contact: Alexander Reichart, MD    +496976014350    reichart.alexander@khnw.de   
Klinikum Aschaffenburg Recruiting
Aschaffenburg, Germany, 63739
Contact: W. Fischbach, Professor    +496021323521    wolfgang.fischbach@klinikum-aschaffenburg.de   
Contact: Christine Klassert    +496021323018    christine.klassert@klinikum-aschaffenburg.de   
Klinikum Bayreuth Recruiting
Bayreuth, Germany, 85445
Contact: Armin A Leitner, MD    +49921400756352    armin.leitner@klinikum-bayreuth.de   
Augusta-Krankenanstalt gGmbH Recruiting
Bochum, Germany, 44791
Contact: Dirk Behringer, Professor    +492345172446    behringer@augusta-bochum.de   
Contact: Dorothee Henzler         
Medizinische Universitaetsklinik Bochum Recruiting
Bochum, Germany, 44892
Contact: Wolf Schmiegel, Professor    +4923429980400      
Contact: Anke Lochter         
Krankenhaus Dresden-Friedrichstadt Recruiting
Dresden, Germany, 01067
Contact: Harald Schmalenberg, MD    +493514804556    harald.schmalenberg@khdf.de   
Universitätsklinikum Dresden Recruiting
Dresden, Germany, 01307
Contact: Gunnar Folprecht, MD    +49351-7965620    gunnar.folprecht@uniklinikum-dresden.de   
Kliniken Essen Mitte Recruiting
Essen, Germany, 45136
Contact: Christian Müller, MD    +4920117424524    ch.mueller@kliniken-essen-mitte.de   
Universitätsklinikum Frankfurt Recruiting
Frankfurt am Main, Germany, 60590
Contact: Oliver Waidmann, MD    +4969-630187788    Oliver.Waidmann@kgu.de   
Universitätsklinik Halle-Wittenberg Not yet recruiting
Halle, Germany, 06120
Contact: Petra Büchner-Steudel, MD    +493455572668    Petra.buechner-steudel@uk-halle.de   
Universitätskrankenhaus Eppendorf Recruiting
Hamburg, Germany, 20246
Contact: Julia Quidde    +490741053343    j.quidde@uke.de   
NCT Heidelberg Recruiting
Heidelberg, Germany, 69120
Contact: Georg M Haag, MD    +496221-56 3 8687    georgmartin.haag@med.uni-heidelberg.de   
Gemeinschaftsklinikum Mittelrhein GmbH Recruiting
Koblenz, Germany, 56068
Contact: Elisabeth Fritz, MD    +492611371941    Elisabeth.fritz@stiftungsklinikum.de   
Universitätsmedizin Mannheim Recruiting
Mannheim, Germany, 68167
Contact: Ralf Hofheinz, Professor    +496213833258    ralf.hofheinz@med3.ma.uni-heidelberg.de   
Contact: Renate Kapaun         
Klinikum rechts der Isar Recruiting
Munich, Germany, 81675
Contact: Hana Algül, MD    +4989-4140 6706    hana.alguel@mri.tum.de   
Klinikum Bogenhausen Recruiting
Munich, Germany, 81925
Contact: Martin Fuchs, MD    +4989-9270 2462    martin.fuchs@klinikum-muenchen.de   
Elblandklinikum Riesa Recruiting
Riesa, Germany, 01589
Contact: Jörg Schubert, Prof.    +49352575 5697    Joerg.Schubert@elblandkliniken.de   
Caritas Klinikum St. Theresia Recruiting
Saarbrucken, Germany, 66113
Contact: Michael Clemens, Prof.    +49681-4061342    m.clemens@caritasklinikum.de   
Sponsors and Collaborators
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest

Additional Information:
Responsible Party: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
ClinicalTrials.gov Identifier: NCT02469480     History of Changes
Other Study ID Numbers: FERINJECT
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018

Keywords provided by IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest:
MCRC
iron substitution
iron deficiency anemia

Additional relevant MeSH terms:
Colorectal Neoplasms
Anemia
Anemia, Iron-Deficiency
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Hematologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Iron
Ferric Compounds
Glycine
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hematinics
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action